本帖最后由 老马 于 2012-1-13 21:20 编辑 ! `; s9 O0 o2 m% A; t; X+ ^
/ {8 Q3 l6 J( B3 a. z! o
爱必妥和阿瓦斯丁的比较
2 v( @ b+ n; k. @
' ?3 |0 @1 j6 @+ Y+ s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/# v: i% F! t+ c. c
. J+ I% o+ \" L' Y) p5 f( C3 C
+ w; Z# C8 i: l- N! v3 A9 N9 vhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
: a z% z8 n4 C3 F3 ^==================================================. b7 E* }/ w& G) V& B. \! H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 _4 S+ F5 ^; ?/ qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 \! o* n7 g, q* S
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- R8 P% X/ G* {! z* d6 B
|